Panobinostat vs Purinostat Mesylate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: HDAC · full Multiple Myeloma pipeline

Panobinostat

Rights held by pharmaand and partners

US approval withdrawn in Multiple Myelomasmall molecule (pan-HDAC inhibitor)
Partial signal

NCT01023308 · Phase 3 · completed

PANORAMA-1 randomly assigned 768 patients with relapsed or relapsed and refractory multiple myeloma to panobinostat or placebo, each with bortezomib and dexamethasone, in a double-blind design. The primary endpoint, investigator-assessed progression-free survival, was met: median 11.99 versus 8.08 months, hazard ratio 0.63 (95% CI 0.52 to 0.76), p<0.0001, per the peer-reviewed publication. Overall survival did not differ significantly at that analysis (HR 0.87, p=0.26).

Reported efficacy

Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. (45 months); Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. (45 months): Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014) (met)

Result source: NCT01023308

Purinostat Mesylate

Developed by Chengdu Zenitar Biomedical Technology

Phase 1/2 in Multiple Myelomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPanobinostatPurinostat Mesylate
PFS, median12.0 vs 8.8+3.2 vs placebon 387NCT01023308
9 other results
—Not reported
OS, median40.3 vs 35.8+4.5 vs placebon 387NCT01023308
8 other results
  • 35 20 mg TIW · n 82 · Phase 2 · secondary NCT02654990
  • 32 20 mg BIW · n 83 · Phase 2 · secondary NCT02654990
  • 17.1 20 mg · n 41 · Phase 1/2 · secondary NCT00918333
  • 22 10 mg TIW · n 83 · Phase 2 · secondary NCT02654990
  • 35.4 30/40 mg · n 20 · Phase 1/2 · secondary NCT00918333
  • 18.4 n 55 · Phase 2 · secondary NCT01083602
  • 21.7 30/40 mg · n 18 · Phase 1/2 · secondary NCT00918333
  • 16.6 20 mg · n 14 · Phase 1/2 · secondary NCT00918333
—Not reported
ORR62.2%b20 mg TIW · wk 24 · n 82NCT02654990
7 other results
  • 65.1% 20 mg BIW · wk 24 · n 83 · Phase 2 · primary NCT02654990
  • 50.6% 10 mg TIW · wk 24 · n 83 · Phase 2 · primary NCT02654990
  • 34.5% wk 24 · n 55 · Phase 2 · primary NCT01083602
  • 62.2% 20 mg TIW · n 82 · Phase 2 · secondary NCT02654990
  • 67.5% 20 mg BIW · n 83 · Phase 2 · secondary NCT02654990
  • 53% 10 mg TIW · n 83 · Phase 2 · secondary NCT02654990
  • 80.6% wk 24 · n 31 · Phase 2 · secondary NCT02290431
—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

Panobinostat
12.0 vs 8.8+3.2 vs placebon 387NCT01023308
9 other results
Purinostat Mesylate
—Not reported

OS, median

Panobinostat
40.3 vs 35.8+4.5 vs placebon 387NCT01023308
8 other results
  • 35 20 mg TIW · n 82 · Phase 2 · secondary NCT02654990
  • 32 20 mg BIW · n 83 · Phase 2 · secondary NCT02654990
  • 17.1 20 mg · n 41 · Phase 1/2 · secondary NCT00918333
  • 22 10 mg TIW · n 83 · Phase 2 · secondary NCT02654990
  • 35.4 30/40 mg · n 20 · Phase 1/2 · secondary NCT00918333
  • 18.4 n 55 · Phase 2 · secondary NCT01083602
  • 21.7 30/40 mg · n 18 · Phase 1/2 · secondary NCT00918333
  • 16.6 20 mg · n 14 · Phase 1/2 · secondary NCT00918333
Purinostat Mesylate
—Not reported

ORR

Panobinostat
62.2%b20 mg TIW · wk 24 · n 82NCT02654990
7 other results
  • 65.1% 20 mg BIW · wk 24 · n 83 · Phase 2 · primary NCT02654990
  • 50.6% 10 mg TIW · wk 24 · n 83 · Phase 2 · primary NCT02654990
  • 34.5% wk 24 · n 55 · Phase 2 · primary NCT01083602
  • 62.2% 20 mg TIW · n 82 · Phase 2 · secondary NCT02654990
  • 67.5% 20 mg BIW · n 83 · Phase 2 · secondary NCT02654990
  • 53% 10 mg TIW · n 83 · Phase 2 · secondary NCT02654990
  • 80.6% wk 24 · n 31 · Phase 2 · secondary NCT02290431
Purinostat Mesylate
—Not reported

VGPR or better

Panobinostat
—Not reported
Purinostat Mesylate
—Not reported

MRD negativity

Panobinostat
—Not reported
Purinostat Mesylate
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Purinostat Mesylate: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Panobinostat: 4 of 4 rows · Purinostat Mesylate: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPanobinostat
Dropout rate
—PAN+BTZa
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
show 31 more results
73.6%Panobinostat + Bortezomib
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
0%20 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
0%20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
0%10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
87.1%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
93.8%
NCT01651039 · Phase 2 · registry result, not featured evidence · combination
—PAN + BTZ + Dex
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePanobinostat + Bortezomib & Dexame
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
11.5%Phase I (Panobinostat + Everolimus
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
5.1%Phase II (Panobinostat + Everolimu
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—45 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—45 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneArm 1, Group X
NCT00621244 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneArm 1, Group Y
NCT00621244 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneArm 2, Group X
NCT00621244 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneArm 2, Group Y
NCT00621244 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—PAN+BTZa
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
show 31 more results
33.6%Panobinostat + Bortezomib
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
—20 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
—20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
—10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
64.5%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
—
NCT01651039 · Phase 2 · registry result, not featured evidence · combination
—PAN + BTZ + Dex
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
20%Panobinostat + Bortezomib & Dexame
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
—Phase I (Panobinostat + Everolimus
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II (Panobinostat + Everolimu
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—45 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—45 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
31.4%Arm 1, Group X
NCT00621244 · Phase 1/2 · registry result, not featured evidence
20.6%Arm 1, Group Y
NCT00621244 · Phase 1/2 · registry result, not featured evidence
27.3%Arm 2, Group X
NCT00621244 · Phase 1/2 · registry result, not featured evidence
8.7%Arm 2, Group Y
NCT00621244 · Phase 1/2 · registry result, not featured evidence
Serious AEs
59.8%PAN+BTZa
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
show 31 more results
—Panobinostat + Bortezomib
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
56.4%20 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
48.2%20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
45%10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
45.2%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
—
NCT01651039 · Phase 2 · registry result, not featured evidence · combination
70.9%PAN + BTZ + Dex
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
—Panobinostat + Bortezomib & Dexame
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
13%Phase I (Panobinostat + Everolimus
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
26.9%Phase II (Panobinostat + Everolimu
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
17.5%
NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination
90.9%80 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
88.9%80 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
69.4%60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
40%60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
77.8%60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
73.3%60 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
88.9%45 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
42.9%45 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
41.7%40 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
90%40 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
75%30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
62.5%30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
83.3%30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
0%30 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
0%20 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
100%20 mg
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—Arm 1, Group X
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—Arm 1, Group Y
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—Arm 2, Group X
NCT00621244 · Phase 1/2 · registry result, not featured evidence
—Arm 2, Group Y
NCT00621244 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 66.7% (placebo 41.1%)
thrombocytopenia 62.5% (placebo 39.8%)
fatigue 40.7% (placebo 28.9%)
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
show 24 more results
20 mg TIW
diarrhoea 65.4%
thrombocytopenia 55.1%
anaemia 42.3%
NCT02654990 · Phase 2 · registry result, not featured evidence
20 mg BIW
diarrhoea 63.9%
thrombocytopenia 44.6%
asthenia 34.9%
NCT02654990 · Phase 2 · registry result, not featured evidence
10 mg TIW
diarrhoea 48.8%
thrombocytopenia 32.5%
anaemia 30%
NCT02654990 · Phase 2 · registry result, not featured evidence
diarrhoea 80.6%
decreased appetite 58.1%
thrombocytopenia 54.8%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70.9%
fatigue 67.3%
nausea 60%
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
hemoglobin decreased 95.7%
platelet count decreased 95.7%
fatigue 91.3%
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
hemoglobin decreased 97.8%
platelet count decreased 90.3%
fatigue 89.2%
NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination
neutropenia 27.5%
thrombocytopenia 25%
lymphopenia 22.5%
NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination
80 mg
diarrhoea 90.9%
fatigue 72.7%
nausea 72.7%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
80 mg
nausea 77.8%
neutropenia 66.7%
thrombocytopenia 66.7%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
60 mg
diarrhoea 83.7%
fatigue 73.5%
anorexia 65.3%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
60 mg
thrombocytopenia 100%
fatigue 60%
hypokalaemia 60%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
60 mg
nausea 77.8%
diarrhoea 66.7%
vomiting 55.6%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
60 mg
fatigue 80%
nausea 80%
thrombocytopenia 73.3%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
45 mg
fatigue 66.7%
diarrhoea 44.4%
dyspnoea 44.4%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
45 mg
fatigue 85.7%
nausea 85.7%
diarrhoea 71.4%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
40 mg
thrombocytopenia 91.7%
fatigue 79.2%
nausea 66.7%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
40 mg
nausea 90%
vomiting 80%
fatigue 70%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
30 mg
thrombocytopenia 100%
diarrhoea 75%
lower respiratory tract infection 50%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
30 mg
diarrhoea 62.5%
fatigue 62.5%
hypokalaemia 62.5%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
30 mg
nausea 66.7%
diarrhoea 50%
fatigue 50%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
30 mg
arthralgia 100%
diarrhoea 100%
epistaxis 100%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
20 mg
arthralgia 100%
back pain 100%
fatigue 100%
NCT00621244 · Phase 1/2 · registry result, not featured evidence
20 mg
anorexia 62.5%
diarrhoea 62.5%
nausea 62.5%
NCT00621244 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Panobinostat

PFS 11.99 vs 8.8 placebo months
time to event · months
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
Overall Survival 40.28 vs 35.78 placebo months
time to event · months
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 60.7% (n=387) vs 54.6% (n=381) placebo
absolute value · percentage points
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Response 1.51 vs 2 placebo months
time to event · months
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response 13.14 vs 10.87 placebo months
time to event · months
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Progression 12.71 vs 8.54 placebo months
time to event · months
NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 62.2% (n=82) @ 24wk20 mg TIW
responder rate · % of participants
No placebo or comparator arm
NCT02654990 · Phase 2 · registry result, not featured evidence
show 7 more results
65.1% (n=83) @ 24wk20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
62.2% (n=82)20 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
67.5% (n=83)20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
50.6% (n=83) @ 24wk10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
53% (n=83)10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
80.6% (n=31) @ 24wk
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
34.5% (n=55) @ 24wk
NCT01083602 · Phase 2 · registry result, not featured evidence · combination
sCR 1.2% (n=82)20 mg TIW
responder rate · % of participants
No placebo or comparator arm
NCT02654990 · Phase 2 · registry result, not featured evidence
show 2 more results
1.2% (n=83)20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
3.6% (n=83)10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
CR 8.5% (n=82)20 mg TIW
responder rate · % of participants
No placebo or comparator arm
NCT02654990 · Phase 2 · registry result, not featured evidence
show 2 more results
8.4% (n=83)20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
2.4% (n=83)10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
VGPR 19.5% (n=82)20 mg TIW
responder rate · % of participants
No placebo or comparator arm
NCT02654990 · Phase 2 · registry result, not featured evidence
show 2 more results
25.3% (n=83)20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
20.5% (n=83)10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
PFS 4.2 months30/40 mg
time to event · months
No placebo or comparator arm
NCT00918333 · Phase 1/2 · registry result, not featured evidence
show 8 more results
4.3 months30/40 mg
NCT00918333 · Phase 1/2 · registry result, not featured evidence
15 months20 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
13 months20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
3.7 months20 mg
NCT00918333 · Phase 1/2 · registry result, not featured evidence
2.3 months20 mg
NCT00918333 · Phase 1/2 · registry result, not featured evidence
8 months10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
15.3 months
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
5.39 months*
NCT01083602 · Phase 2 · registry result, not featured evidence · combination · converted to months from 164 days as posted
Overall Survival 35.4 months30/40 mg
time to event · months
No placebo or comparator arm
NCT00918333 · Phase 1/2 · registry result, not featured evidence
show 8 more results
21.7 months30/40 mg
NCT00918333 · Phase 1/2 · registry result, not featured evidence
35 months20 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
32 months20 mg BIW
NCT02654990 · Phase 2 · registry result, not featured evidence
17.1 months20 mg
NCT00918333 · Phase 1/2 · registry result, not featured evidence
16.6 months20 mg
NCT00918333 · Phase 1/2 · registry result, not featured evidence
22 months10 mg TIW
NCT02654990 · Phase 2 · registry result, not featured evidence
NA months
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
18.37 months*
NCT01083602 · Phase 2 · registry result, not featured evidence · combination · converted to months from 559 days as posted

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Panobinostat's landscape · Purinostat Mesylate's landscape